Partnering Opportunities

Affibodys partnering strategy is to engage in partnerships centered around: 

  • Target-by-target development of novel biotherapeutics (discovery collaborations), or
  • Out-licensing of Albumod™ technology

For opportunities for collaborative, partnership or licensing agreements, please contact

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)